Gene therapies for mucopolysaccharidoses

Area of Science:

• Biomedical research
• Genetic medicine
• Rare diseases

Background:

• Current mucopolysaccharidoses (MPSs) treatments, enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT), have significant limitations.
• These limitations include poor efficacy for brain and skeletal issues, the need for lifelong treatment, and high costs.
• There is a critical need for more effective therapeutic strategies for MPSs.

Purpose of the Study:

• To review the latest clinical progress in gene therapy for mucopolysaccharidoses (MPSs).
• To discuss various gene therapy approaches, including their advantages and disadvantages.
• To highlight the potential of gene therapy to overcome the limitations of current MPSs treatments.

Main Methods:

• Review of recent clinical studies and advancements in gene therapy for MPSs.
• Analysis of ex vivo gene therapy using gene-modified hematopoietic stem progenitor cells.
• Evaluation of in vivo gene therapy involving direct viral vector infusion.

Main Results:

• Gene therapy aims to achieve sustained therapeutic enzyme levels in multiple tissues.
• Both ex vivo and in vivo gene therapy approaches are being explored for MPSs treatment.
• Recent clinical progress indicates potential for improved efficacy and reduced treatment burden.

Conclusions:

• Gene therapy represents a significant advancement in the treatment of mucopolysaccharidoses.
• Further research and clinical trials are essential to optimize gene therapy strategies.
• Gene therapy holds promise for addressing the unmet needs in MPSs management, particularly for neurological and skeletal complications.